<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="221">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 14, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01845675</url>
  </required_header>
  <id_info>
    <org_study_id>TEPNET</org_study_id>
    <nct_id>NCT01845675</nct_id>
  </id_info>
  <brief_title>Temozolomide Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Temozolomide combined with endostatin have efficacy in well-differentiated pancreatic
      neuroendocrine tumor
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>From date of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>From date of treatment until the date of death,  assessed up to 5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Advanced Well-differentiated Pancreatic Neuroendocrine Tumor</condition>
  <arm_group>
    <arm_group_label>temozolomide, endostatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endostatin 15mg/d，IV infusion, d1-d14 Temozolomide 150-200mg/m2/d，p.o., d1-d7。 Repeat every 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide combined with endostatin</intervention_name>
    <arm_group_label>temozolomide, endostatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 years of age and older

          2. ECOG ≤2

          3. Pathologically confirmed locally advanced or metastatic well-differentiated
             pancreatic neuroendocrine tumor（G1,G2）

          4. Prior treatment with one-line chemotherapy is allowed, with the exception of prior
             treatment with temozolomide or dacarbazine or endostatin within the past 6 months

          5. Disease progressed during or after last therapy

          6. Minimum of 4 weeks since any major surgery, completion of radiation, or completion of
             all prior systemic anticancer therapy

          7. Disease progressed within the past 12 months。

          8. Patients must have at least one measurable site of disease according to RECIST1.1
             criteria that has not been previously irradiated.

          9. Adequate bone marrow, liver and renal function

         10. Life expectancy 3 months or more

         11. Patient informed consent。

        Exclusion Criteria:

          1. Concurrent use of Octreotide or other drug that may have efficacy in neuroendocrine
             tumor.

          2. 2 or more lines of prior chemotherapy。

          3. Patients who have any severe and/or uncontrolled medical conditions or other
             conditions that could affect their participation in the study

          4. Uncontrolled infectious disease。

          5. Other malignancies within the past 5 years except for adequately treated carcinoma of
             the cervix or basal or squamous cell carcinoma of the skin

          6. Uncontrolled brain or leptomeningeal metastases

          7. Patients with known hypersensitivity to temozolomide or endostatin。

          8. Patient could not take tablets。
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yuejuan Cheng, M.D.</last_name>
    <phone>861069158315</phone>
    <email>cnchengyuejuan@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Division of Medical Oncology, Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuejuan Cheng, M.D.</last_name>
      <phone>861069158315</phone>
      <email>cnchengyuejuan@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Yuejuan Cheng, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 16, 2013</lastchanged_date>
  <firstreceived_date>April 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>YueJuan Cheng</investigator_full_name>
    <investigator_title>attending medical oncologist</investigator_title>
  </responsible_party>
  <keyword>temozolomide</keyword>
  <keyword>endostatin</keyword>
  <keyword>advanced</keyword>
  <keyword>well-differentiated</keyword>
  <keyword>pancreatic neuroendocrine tumor</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenoma, Islet Cell</mesh_term>
    <mesh_term>Apudoma</mesh_term>
    <mesh_term>Carcinoid Tumor</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Endostatins</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
